Rare Cancers, Common Need

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 
Sandip Patel
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
Young Kwang Chae
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login